SCHEMBL16138447

SCHEMBL16138447

NC(=O)C[C@H](N)C(=O)C(=O)[C@@H](N)CC(=O)O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX15 P16050 1/20 0.39
BLM P54132 1/20 0.39
PMP22 Q01453 1/20 0.39
KMT2A Q03164 1/20 0.39
SLC22A6 Q4U2R8 1/20 0.38
GABRR1 P24046 2/20 0.37
LMNA P02545 1/20 0.37
TDP1 Q9NUW8 1/20 0.36
GRIK1 P39086 2/20 0.36
GRIK2 Q13002 2/20 0.36
GRM1 Q13255 2/20 0.36
GRM2 Q14416 2/20 0.36
GRM8 O00222 1/20 0.36
GRM6 O15303 1/20 0.36
GRIN2D O15399 1/20 0.36
GRIN3B O60391 1/20 0.36
GSR P00390 1/20 0.36
CYP1A2 P05177 1/20 0.36
GRM5 P41594 1/20 0.36
GRIA1 P42261 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17921870 0.89 SLC22A6 (0.45) SLC22A6GABRR1LMNATDP1GRIK1
Asparagine SCHEMBL366069 0.85 ALOX15 (0.50) ALOX15BLMPMP22KMT2ATDP1
SCHEMBL27591273 0.85 ALOX15 (0.39) ALOX15BLMPMP22KMT2ASLC22A6
Asparagine SCHEMBL7998952 0.85 ALOX15 (0.50) ALOX15BLMPMP22KMT2ATDP1
Asparagine SCHEMBL366070 0.85 ALOX15 (0.50) ALOX15BLMPMP22KMT2ATDP1
Asparagine SCHEMBL10011961 0.85 ALOX15 (0.50) ALOX15BLMPMP22KMT2ATDP1
Asparagine SCHEMBL7998953 0.85 ALOX15 (0.50) ALOX15BLMPMP22KMT2ATDP1
Asparagine SCHEMBL6520765 0.83 ALOX15 (0.48) ALOX15BLMPMP22KMT2ATDP1
Asparagine SCHEMBL5327761 0.83 ALOX15 (0.48) ALOX15BLMPMP22KMT2ATDP1
SCHEMBL17636172 0.80 GABRR1 (0.42) SLC22A6GABRR1LMNATDP1GRIK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2017186669-A1 STREPTAVIDIN MUTEINS AND METHODS OF USING THEM IBA GMBH (DE) 2017-11-02 WO disclosed
WO-2015021358-A2 COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT CHARMOT DOMINIQUE (US) 2015-02-12 WO disclosed
US-20140294762-A1 GLYCOPEGYLATION METHODS AND PROTEINS/PEPTIDES PRODUCED BY THE METHODS NOVO NORDISK A/S (DK) 2014-10-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140294762-A1 GLYCOPEGYLATION METHODS AND PROTEINS/PEPTIDES PRODUCED BY THE METHODS PTMS, ANPEP, NGLY1 ALOX15 4528/4885BLM 4437/4885PMP22 1805/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.